


# Peroxisomal integrity in demyelination-associated microglia enables cellular debris clearance and myelin renewal in mice

Joseph A. Barnes-Vélez, Xiaohong Zhang, Yaren L. Peña Señeriz, Kiersten A. Scott, Yinglu Guan, Jian Hu

*J Clin Invest.* 2025. <https://doi.org/10.1172/JCI179985>.

Research In-Press Preview Cell biology Inflammation Neuroscience

## Graphical abstract



Find the latest version:

<https://jci.me/179985/pdf>



1 **Title Page**

2 **Manuscript title**

3 *Peroxisomal integrity in demyelination-associated microglia enables cellular debris clearance*  
4 *and myelin renewal in mice*

5 **Authors and affiliations**

6 Joseph A. Barnes-Vélez<sup>1,2,3</sup>, Xiaohong Zhang<sup>1</sup>, Yaren L. Peña Señeriz<sup>4</sup>, Kiersten A Scott<sup>2</sup>, Yinglu  
7 Guan<sup>1</sup>, and Jian Hu<sup>1,2,5</sup>

8 <sup>1</sup>Department of Cancer Biology, MD Anderson Cancer Center, Houston, Texas, USA, 77030;

9 <sup>2</sup>University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical

10 Sciences, Houston, Texas, USA, 77030; <sup>3</sup>University of Puerto Rico School of Medicine, San Juan,

11 Puerto Rico, 00936; <sup>4</sup>University of Puerto Rico at Cayey, Cayey, Puerto Rico, 00736; <sup>5</sup>Cancer

12 Neuroscience Program, MD Anderson Cancer Center, Houston, Texas, USA, 77030

13  
14 **Corresponding author:** Jian Hu, 1881 East Rd, South Campus Research Building 3, Houston,

15 Texas, USA, 77030. Phone: 713-794-5238. Email: [jhu3@mdanderson.org](mailto:jhu3@mdanderson.org)


16  
17 **Conflict-of-interest statement**

18 The authors have declared that no conflict of interest exists.

20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39

## Abstract

Demyelination associated microglia (DMAM) orchestrate the regenerative response to demyelination by clearing myelin debris and promoting oligodendrocyte maturation. Peroxisomal metabolism has emerged as a candidate regulator of DMAMs, though the cell-intrinsic contribution in microglia remains undefined. Here we elucidate the role of peroxisome integrity in DMAMs using cuprizone mediated demyelination coupled with conditional knockout of peroxisome biogenesis factor 5 (PEX5) in microglia. Absent demyelination, PEX5 conditional knockout (PEX5cKO) had minimal impact on homeostatic microglia. However, during cuprizone-induced demyelination, the emergence of DMAMs unmasked a critical requirement for peroxisome integrity. At peak demyelination, PEX5cKO DMAMs exhibited increased lipid droplet burden and reduced lipophagy suggestive of impaired lipid catabolism. Although lipid droplet burden declined during the remyelination phase, PEX5cKO DMAMs accumulated intralysosomal crystals and curvilinear profiles, which features were largely absent in controls. Aberrant lipid processing was accompanied by elevated lysosomal damage markers and downregulation of the lipid exporter gene *ApoE*, consistent with defective lipid clearance. Furthermore, the disruptions in PEX5cKO DMAMs were associated with defective myelin debris clearance and impaired remyelination. Together, these findings delineate a stage-specific role for peroxisomes in coordinating lipid processing pathways essential to DMAM function and necessary for enabling a pro-remyelinating environment.



Homeostatic microglia



Demyelination associated microglia



Myelin debris



Lipid droplets



Polymorphic electron dense lysosomes



Crystal clefts



Curvilinear profiles

40

41 Loss of peroxisomal integrity disrupts myelin debris-derived lipid processing in demyelination

42 associated microglia and undermines myelin debris clearance and remyelination.

43

## Main Text

### 45 **Introduction**

46 Peroxisomes are single membrane bound organelles required for a subset of metabolic pathways,  
47 including ether lipid synthesis and very long chain fatty acid oxidation (1). Recently, evidence  
48 linking peroxisomes to immunometabolism (2) has been described in macrophages, wherein  
49 through cell intrinsic mechanisms peroxisomes facilitate pathogen clearance (3), cytokine release  
50 (4), and bioactive lipid precursor mobilization (5). Moreover, peroxisomal lipid oxidation regulates  
51 adaptations to age-related stress in microglia, the predominant subset of brain resident  
52 macrophages (6, 7). Microglia drive a critical response to demyelination by clearing myelin debris  
53 and enabling newly formed oligodendrocytes to remyelinate denuded axons (8). Studies in  
54 peroxisomal disease have suggested that peroxisomes also contribute to DMAMs and the  
55 microglial response in demyelination. For instance, in adrenoleukodystrophy, germline mutations  
56 disrupting peroxisomal lipid oxidation can precipitate demyelination associated with perilesional  
57 microglial stress and loss (9, 10). However, whether peroxisomes facilitate DMAMs cell  
58 autonomously and to what extent remain unclear.

59 To ascertain the cell intrinsic role of peroxisomes in DMAMs, we disrupted peroxisome  
60 biogenesis in microglia by conditional depletion of PEX5 (encoded by *Pex5*) within the context of  
61 cuprizone induced demyelination. PEX5 loss redirected microglial activation into DMAMs  
62 enriched for lysosome damage related genes *Lgals3* and *Gpnmb*. In contrast to peroxisome intact  
63 DMAMs, lipid droplet clearance in PEX5cKO DMAMs correlated with notable crystal  
64 accumulation and loss of lipophagy-invoking structures. Moreover, PEX5 depletion in DMAMs  
65 reduced myelin debris clearance and pro-remyelination factor expression which correlated with

66 impaired remyelination. In summary, the microglial response during demyelination is intrinsically  
67 dependent on peroxisomal integrity for acquiring a pro-remyelinating phenotype.

## 68 **Results**

### 69 **Validation of PEX5 depletion in myeloid cells**

70 We asked whether microglia intrinsically depend on peroxisomes to facilitate a response to  
71 demyelination. To address this question, we achieved PEX5cKO using *Cx3cr1*<sup>CreERT2/wt</sup>, *Pex5*<sup>lox/lox</sup>  
72 mice (11, 12), in which tamoxifen-inducible Cre recombinase drives PEX5 depletion in myeloid  
73 cells, including microglia. *Cx3Cr1*<sup>CreERT2/wt</sup>, *Pex5*<sup>lox/wt, wt/wt</sup> littermates served as controls. In vitro,  
74 4-hydroxytamoxifen exposure downregulated both *Pex5* mRNA and PEX5 protein in PEX5cKO  
75 bone marrow-derived macrophages relative to control (Supplemental Figure 1 A, B, C). Since  
76 PEX5 loss undermines peroxisome biogenesis (13), we examined peroxisome integrity.  
77 Immunolabeling for peroxisome membrane protein 70 (PMP70) revealed that PEX5cKO  
78 macrophages, relative to control, exhibited fewer and larger PMP70<sup>+</sup> punctae, suggestive of  
79 enlarged ghost peroxisomes or peroxisomal clumping (Supplemental Figure 1D,E,F) indicative of  
80 disrupted peroxisome homeostasis (13).

### 81 **Experimental design to assess the role of PEX5 in DMAMs**

82 To evaluate the effects of PEX5 loss in DMAMs, we fed adult PEX5cKO and control littermates  
83 0.2% cuprizone diet for 6 weeks (Supplemental Figure 1G). Two weeks prior to starting cuprizone,  
84 both PEX5cKO and control littermates received tamoxifen (2 mg daily, five consecutive days) to  
85 induce PEX5 knockout and enable turnover of healthy peroxisomes to dysfunctional peroxisomes  
86 (14). After six weeks with cuprizone, brain samples were collected to assess peak demyelination  
87 (CPZ). Baseline condition consisted of PEX5cKO and control littermates kept on standard chow

88 throughout the study (Supplemental Figure 1G). Whole brain samples were collected and  
89 submitted to single nuclei RNA sequencing for transcriptional profiling of the cell types of interest.

### 90 **PEX5 loss diverges DMAM evolution following demyelination**

91 Following quality control, dimensionality reduction, cell clustering, and cell marker-based  
92 annotation (Supplemental Figure 2A, B, C; Supplemental Table 1), we detected 29 cell clusters,  
93 24 of which were neuronal (*Syt1* enriched) and further categorized into glutamatergic (*Slc17a7*,  
94 *Slc17a6* expressing) and GABAergic (*Gad1*, *Gad2* expressing) subtypes (Figure 1A, B;  
95 Supplemental Figure 2C). Non-neuronal clusters included oligodendrocytes, immune cells,  
96 oligodendrocyte progenitor cells (OPC), astrocytes, and vascular leptomeningeal cells (VLMC)  
97 (Figure 1A; Supplemental Figure 2C). CPZ samples exhibited oligodendrocyte loss alongside  
98 increased immune cell and OPC counts relative to baseline (Figure 1B), which findings were  
99 consistent with oligodendrocyte cell death, inflammation, and increased remyelination-mediating  
100 OPCs expected with cuprizone exposure (15).

101 As PEX5 loss was targeted to myeloid cells and microglia, we performed immune cell sub-  
102 analysis. Among immune cells, we detected 9 subclusters, of which 7 were comprised of microglia,  
103 characterized by *Hexb* and *Tgfbri* enrichment (Figure 1C, D, E; Supplemental Table 2). The  
104 remaining two non-microglial clusters included macrophages (*Mrc1*, *F13a1* expressing) and  
105 lymphocytes (*Skap1*, *Itk* expressing) (Figure 1E). Under baseline conditions, the bulk of microglia  
106 expressed homeostatic genes *P2ry12* and *Cx3cr1* (16) (Figure 1C, E, F).

107 Within the CPZ arm, microglia underwent a marked shift in cell states. Microglia exhibiting  
108 intermediate expression of activation-related genes (*Axl*, *ApoE*) were labeled as Intermediate  
109 microglia (Figure 1E). Microglia that strongly upregulated activation-related genes and  
110 downregulated homeostatic genes were classified as DMAMs and were subclassified into 3

111 clusters labeled as DMAM0, DMAM1, and DMAM2 (Figure 1E). Relative to DMAM0, the  
112 DMAM1 and DMAM2 clusters acquired additional markers beyond hallmark activation genes.  
113 Among marker genes, DMAM1 exhibited high expression of *Lpl* and *Csf1* and intermediate  
114 expression of *Lgals3*, whereas DMAM2 demonstrated high expression of *Lgals3* and high  
115 expression for *GpnmB* (Figure 1C, E). Consistent with an inflammatory response, we also  
116 identified proliferating microglia (Cycling) and interferon responsive microglia (IRM) enriched  
117 for interferon pathway genes (Figure 1E).

118 Notably, the DMAM2 cluster was almost exclusively identified in PEX5cKO samples  
119 within the CPZ arm, whereas control DMAMs predominantly consisted of DMAM0 and DMAM1  
120 clusters (Figure 1F). Fold change analysis confirmed a significant increase in the DMAM2 cell  
121 fraction in PEX5cKO CPZ samples, accompanied by a reduction in DMAM0 and DMAM1 cell  
122 fractions relative to control CPZ samples (Figure 1G). We next performed pseudotime analysis to  
123 elucidate the developmental trajectory of the DMAM clusters (17). Selecting homeostatic  
124 microglia as the origin cluster, pseudotime analysis revealed a sequential developmental trajectory  
125 of homeostatic microglia into Intermediate and DMAM0 microglia (Figure 1H). From DMAM0  
126 state, activated microglia then diverged into DMAM1 or DMAM2 states (Figure 1H, I, J).  
127 Coupling pseudotime and fold change analyses indicated that PEX5cKO reprogrammed the  
128 DMAM evolution, redirecting DMAMs away from the DMAM1 state and towards the PEX5cKO-  
129 enriched DMAM2 state.

### 130 **PEX5cKO undermines *ApoE* expression in activated microglia**

131 To identify molecular changes driving the altered DMAM states downstream of PEX5 depletion,  
132 we performed pseudobulk analysis comparing control and PEX5cKO genotypes across the  
133 immune clusters within the CPZ arm. Using an adjusted p value cutoff of 0.15, we identified

134 relatively few differentially expressed genes (DEGs) across the subclusters (Figure 2A;  
135 Supplemental Table 3). No DEGs were identified in the DMAM2 cluster, likely because the cluster  
136 was predominantly comprised of PEX5cKO cells (Figure 2A). However, triangulation of  
137 downregulated DEGs revealed that *ApoE* expression was decreased in PEX5cKO samples across  
138 the DMAM0, DMAM1, and Intermediate clusters (Figure 2B). The *ApoE* gene encodes for  
139 apolipoprotein E (APOE), a critical activation-related protein. *ApoE* expression is strongly induced  
140 in DMAMs following demyelination, as was observed in our single nuclei RNA sequencing data  
141 (Figure 2C), which demonstrated both increased average as well as higher percent expression of  
142 *ApoE* in Intermediate and DMAM clusters relative to homeostatic microglia. However, *ApoE*  
143 expression in the Intermediate and DMAM clusters was significantly impaired in PEX5cKO  
144 samples (Figure 2D). Thus, *ApoE* expression in the context of cuprizone-induced demyelination is  
145 dependent on PEX5 and presumably peroxisome integrity in microglia.

146 **Impaired *ApoE* expression correlates with exacerbated lipid droplet accumulation and**  
147 **crystal precipitation in PEX5cKO tissue**

148 Following cell debris uptake, DMAMs upregulate lipid droplet biogenesis and *ApoE* dependent  
149 lipid export (18). *ApoE* downregulation and impaired lipid export undermine the pro-remyelinating  
150 properties and exacerbate lipid droplet burden in microglia (19). To assess for lipid droplets, we  
151 performed transmission electron microscopy (TEM) to quantitate lipid droplets within lesion-  
152 associated phagocytes. Additionally, to assess the impact of PEX5 depletion on remyelination, a  
153 third experimental arm was added, wherein after six weeks of cuprizone diet, PEX5cKO and  
154 control littermates were switched back to standard chow for ten days (postCPZ) (Supplemental  
155 Figure 1G).

156 Using TEM, lipid droplets were visualized in CPZ and postCPZ conditions relative to  
157 baseline, consistent with the expected increase in lipid droplet biogenesis in DMAMs during  
158 demyelination (Figure 2E, F, G). In agreement with impaired *ApoE* gene expression, we observed  
159 that lipid droplet counts per phagocyte were elevated in PEX5cKO relative to control at both the  
160 CPZ and postCPZ conditions (Figure 2E, F, G). Lipid droplet burden peaked in the CPZ arm and  
161 declined in the postCPZ arm for both PEX5cKO and control, indicative that although PEX5 loss  
162 exacerbated lipid droplet burden, lipid droplet clearance remained intact (Figure 2E, F, G).

163 Lipid droplet processing requires the export of cholesterol via lipoproteins, including  
164 APOE (20). Control DMAMs expressing APOE are expected to more effectively extrude lipids  
165 via lipoprotein-dependent mechanisms. *ApoE* downregulation in PEX5cKO DMAMs suggest that  
166 the resolution of lipid droplets was associated with defective lipid export. Impaired lipid export  
167 following lipid droplet catabolism can lead to aberrant accumulation of lipids in other subcellular  
168 structures, including lipid crystals (19). Elevated intracellular sterol concentration secondary to  
169 APOE loss in myelin debris clearing microglia is associated with sterol crystal precipitation (19).  
170 Accordingly, we observed a marked increase in crystal clefts within PEX5cKO phagocytes (Figure  
171 2H, I). Both frequency of crystal positive phagocytes and per cell crystal burden peaked in  
172 PEX5cKO postCPZ samples, following an inverse trend relative to lipid droplet burden (Figure  
173 2H, I). In contrast, crystals were less frequently observed in control samples during demyelination  
174 and remained undetected within control postCPZ samples (Figure 2H, I). Therefore, unlike in  
175 control, lipid droplet resolution in PEX5cKO samples was directly associated with crystal  
176 accumulation.

177 Consistent with the TEM analysis, lipid droplets were readily detected in lectin<sup>+</sup>  
178 phagocytes following demyelination using BODIPY dye (Figure 2J). Although BODIPY<sup>+</sup> cell

179 counts resolved in the postCPZ arm across genotypes (Figure 2K), BODIPY<sup>+</sup> punctae remained  
180 increased in PEX5cKO lectin<sup>+</sup> phagocytes relative to control (Figure 2L), thus validating our TEM  
181 assessment that PEX5 loss exacerbated lipid droplet burden without blocking lipid droplet  
182 resolution. Crystals in tissue can be detected as reflective particles using reflection microscopy.  
183 Accordingly, dual confocal and reflection microscopy detected microclusters of reflective particles  
184 within lectin<sup>+</sup> phagocytes at both the CPZ and postCPZ conditions (Figure 2M, N). Importantly,  
185 the average area for reflective particle microclusters was significantly higher in PEX5cKO lectin<sup>+</sup>  
186 phagocytes relative to control and increased in the postCPZ relative to CPZ conditions, suggestive  
187 of higher crystal burden in PEX5cKO postCPZ samples following lipid droplet resolution (Figure  
188 2M, N). Thus, our tissue staining, reflective microscopy, and electron microscopy data are  
189 consistent with impaired lipid processing in PEX5cKO DMAMs.

190 In summary, control samples exhibited an expected pattern of lipid droplet biogenesis and  
191 resolution within CPZ and postCPZ conditions. In contrast, PEX5cKO DMAMs exhibited an  
192 exacerbated burden of lipid droplets and accumulation of intracellular crystals correlating with  
193 lipid droplet resolution.

#### 194 **Impaired lipophagy in PEX5cKO correlates with intralysosomal crystals and curvilinear** 195 **profiles**

196 Lipid droplets are processed in part by lipophagy, which enables autophagy mediated lipid  
197 catabolism through fusion of lipid droplets with lysosomes (21, 22). In control samples following  
198 cuprizone mediated demyelination, large (0.75  $\mu\text{m}^2$  and 1.08  $\mu\text{m}^2$  median areas in CPZ and  
199 postCPZ arms, respectively), polymorphic, electron-dense lysosomes (PEDLs) were observed  
200 fusing with lipid droplets within phagocytes, suggestive of lipophagy (Figure 3A). The frequency

201 and intracellular count of PEDLs peaked during demyelination and correlated with the peak lipid  
202 droplet density described above (Figure 3B, C).

203 Interestingly, relative to control, PEDLs were scarcer in PEX5cKO phagocytes (Figure 3B,  
204 C) and presented with smaller areas ( $0.65 \mu\text{m}^2$  and  $0.51 \mu\text{m}^2$  median areas in CPZ and postCPZ,  
205 respectively) (Figure 3D). Moreover, PEX5cKO phagocytes exhibited a higher incidence of crystal  
206 clefts within PEDLs (Figure 3E), suggestive of impaired lipid extraction from lysosomes, leading  
207 to lipid accumulation and crystal precipitation. Thus, loss of PEX5 and peroxisome integrity  
208 present with findings suggestive of impaired intracellular lipid processing following debris  
209 engulfment, including lipophagy disruption and accumulation of intralysosomal crystals.

210 Additional to intralysosomal crystal accumulation, we observed the formation of  
211 hypodense, curvilinear profiles within PEX5cKO phagocytes during and after cuprizone exposure  
212 (Figure 3F), with more than 50% of PEX5cKO phagocytes in the postCPZ condition presenting  
213 with the same (Figure 3G). Pathology reports described the occurrence of laminar profiles in brain  
214 phagocytes in cases with adrenoleukodystrophy that were hypothesized to consist of lipid deposits  
215 with very long chain fatty acids (23, 24). The enrichment of curvilinear profiles in PEX5cKO  
216 phagocytes therefore raises the possibility of a convergence in pathologies between brain  
217 phagocytes in cuprizone-fed PEX5cKO mice and adrenoleukodystrophy.

### 218 **PEX5cKO DMAMs exhibit exacerbated GAL3 response and lysosome turnover**

219 Intralysosomal crystals can compromise lysosome integrity and induce cell stress (19).  
220 Accordingly, PEX5cKO samples exhibited a significantly higher number of cycling microglia  
221 (Figure 1G), suggestive of higher microglial turnover secondary to cell death from lysosome  
222 injury. Additionally, single nuclei RNA sequencing revealed an increase in *Lgals3* expression in  
223 DMAM2 state enriched in PEX5cKO samples (Figure 1E). *Lgals3* encodes for galectin 3 (GAL3),

224 a glycoprotein-binding factor involved in lysosome damage response (25, 26). Whereas *Lgals3*  
225 was near undetectable in homeostatic and Intermediate microglial clusters, *Lgals3* achieved low  
226 expression in DMAM0 and IRM clusters, and intermediate and high expression in DMAM1 and  
227 DMAM2 clusters, respectively (Figure 1E). The expression pattern for *Lgals3* is consistent with  
228 previous reports describing GAL3 upregulation in activated but not resting microglia (27).  
229 Consistent with the paucity of DMAMs at baseline condition, immunofluorescence analysis  
230 demonstrated that GAL3<sup>+</sup> cells were nearly undetectable in both control and PEX5cKO baseline  
231 samples (Figure 4A, B). In the CPZ arm, GAL3<sup>+</sup> cell counts significantly increased, reflecting the  
232 emergence of DMAMs during demyelination. In the postCPZ arm, GAL3<sup>+</sup> cell counts dropped,  
233 consistent with a resolution in demyelination (Figure 4A, B). Overall, GAL3<sup>+</sup> staining correlated  
234 with the expected dynamics for DMAM cell counts associated with cuprizone use.

235 GAL3<sup>+</sup> cell counts did not substantially differ between PEX5cKO and control under CPZ  
236 and postCPZ conditions (Figure 4B). However, in agreement with the transcriptomic analysis,  
237 PEX5 depletion increased GAL3 staining intensity per cell relative to control following cuprizone  
238 mediated demyelination (Figure 4C). Thus, PEX5 knockout promoted a shift favoring GAL3-high  
239 expressing DMAMs, congruent with the enrichment of *Lgals3*-high expressing DMAM2 cluster  
240 in PEX5cKO samples.

241 Additional to increased GAL3 expression, PEX5cKO DMAMs also exhibited greater  
242 formation of intracellular GAL3<sup>+</sup> punctae that frequently co-labeled with lysosomal associated  
243 membrane protein 1 (LAMP1) (Figure 4D, E). Following lysosome injury, GAL3 localizes to the  
244 exposed lysosomal lumen enabling a signaling cascade driving lysosome repair and turnover (28).  
245 GAL3 upregulation and robust formation of GAL3<sup>+</sup> punctae in PEX5cKO DMAMs suggested an  
246 intact response to lysosome injury expected with intralysosomal crystals detected with TEM.

247 Accordingly, using DEG and pathway enrichment analyses between clusters, we observed that  
248 relative to both DMAM1 and DMAM0, the DMAM2 cluster was significantly enriched for the  
249 lysosome gene pathway, compatible with elevated lysosome turnover secondary to injury and  
250 expected with an activated, GAL3-dependent injury response. (Figure 4F, G; Supplemental Table  
251 4).

252 All together transcriptomic and imaging data indicate that PEX5 knockout and loss of  
253 peroxisome integrity undermine lysosome mediated degradation of lipids traceable through  
254 intralysosomal crystals, GAL3 upregulation and redistribution, and increased lysosome turnover.

### 255 **Myelin debris uptake in PEX5cKO macrophages can partially reproduce the DMAM2** 256 **cluster-associated signature**

257 Our data indicate that DMAMs responding to demyelination depend on PEX5 for mitigating  
258 crystal accumulation. A primary function of DMAMs includes myelin debris clearance. To assess  
259 whether perturbations in PEX5cKO DMAMs were unmasked by myelin debris uptake, we asked  
260 whether challenging PEX5cKO macrophages with myelin debris could replicate DMAM2 cluster-  
261 associated signatures.

262 We generated bone marrow-derived macrophages from control and PEX5cKO littermates.  
263 In all conditions, culture medium was supplemented with 4-hydroxytamoxifen to enable PEX5  
264 depletion. Macrophages were supplemented with purified myelin debris for 24 (24h) and 72 hours  
265 (72h) and collected for bulk RNA sequencing. Myelin debris naïve macrophages (resting) served  
266 as baseline references (Supplemental Figure 3A).

267 Principal component and DEG analyses demonstrated that PEX5 knockout had a subdued  
268 impact under baseline conditions, with minimal separation between resting macrophage  
269 transcriptomes (Supplemental Figure 3B), consistent with our findings in vivo where PEX5cKO

270 and control homeostatic microglia remained comparable. Next, following myelin debris  
271 engulfment, macrophage transcriptomes diverged significantly between PEX5cKO and control  
272 genotypes (Supplemental Figure 3B), with DEGs rising to 244 at 24 hours, and further climbing  
273 to 1115 following 72 hours of myelin debris exposure (Supplemental Figure 3C, D; Supplemental  
274 Table 5). The higher DEG count in bone marrow-derived macrophages relative to DMAMs likely  
275 reflected a higher sensitivity to transcriptomic changes afforded by deeper bulk sequencing relative  
276 to single nuclei RNA sequencing, inherent differences between bone marrow-derived macrophages  
277 and microglia and between in vitro and in vivo conditions. However, 16 of 87 DEGs upregulated  
278 in the DMAM2 cluster relative to DMAM1 were also upregulated in PEX5cKO macrophages  
279 relative to control after 72 hours of myelin exposure (Supplemental Figure 3E). Importantly, the  
280 shared DEGs included *Gpnmb* and *Lgals3* (Supplemental Figure 3E, F). Additionally, pathway  
281 enrichment analysis exhibited enrichment for lysosome pathways in PEX5cKO macrophages  
282 relative to control across both timepoints of myelin debris exposure, as had been seen with  
283 DMAM2 (Supplemental Figure 3G). Interestingly, *ApoE* expression was not affected by PEX5  
284 status in bone marrow-derived macrophages, either at baseline or following myelin debris  
285 exposure, indicative that reliance of *ApoE* expression on PEX5 remains context or cell type  
286 dependent (Supplemental Figure 3F). However, Ingenuity pathway upstream regulator activity  
287 analysis inferred impaired APOE activity at both timepoints of myelin debris exposure  
288 (Supplemental Figure 3H), indicative that although *ApoE* expression remained intact in PEX5cKO  
289 macrophages, APOE related pathways were deficient, including reduced expression of *Abca1*  
290 (Supplemental Figure 3F). Finally, gene set enrichment analysis of transcriptional signatures  
291 derived from published single cell RNA sequencing datasets demonstrated that foamy microglia  
292 signatures were enriched in PEX5cKO macrophages relative to control post myelin debris uptake

293 (Supplemental Figure 3I; Supplemental Table 6), consistent with the exacerbated lipid laden  
294 phenotype we observed in vivo in PEX5cKO DMAMs.

295 In summary, myelin debris uptake in PEX5cKO bone marrow-derived macrophages can  
296 partially reproduce the molecular signature associated the DMAM2 cluster, indicative that myelin  
297 debris uptake in PEX5cKO phagocytes is a contributing factor to DMAM2 cluster emergence.

### 298 **Emergence of DMAM2 cluster in PEX5cKO samples correlates with impaired remyelination**

299 To assess the impact of DMAM disruption on remyelination, we analyzed the oligodendroglia  
300 lineage within the single nuclei RNA sequencing dataset. Our dataset included OPCs and 9  
301 subclusters of *Mbp*<sup>+</sup> oligodendrocytes (Supplemental Figure 4A, C; Supplemental Table 7). Cell  
302 marker annotation elucidated committed oligodendrocyte progenitors and newly formed  
303 oligodendrocytes (COP/NFOL) notable for *Frm4da* and *Tcf7l2* enrichment (Supplemental Figure  
304 4A, C), myelin-forming oligodendrocytes (MFOL) which upregulated *Man1a* and *Synpr* and  
305 myelin genes including *Mog* and *Mobp* (Supplemental Figure 4A, C), and mature oligodendrocytes  
306 (MOL), which downregulated immature marker *Pcdh7* and upregulated MOL subtype 5/6  
307 (MOL5/6) associated genes *Il33* and *Ptgds* or MOL subtype 2 (MOL2) associated gene *Anln*  
308 (Supplemental Figure 4A, C). We also detected two additional variations of MOL5/6 notable for  
309 enrichment of *Adgrv1* (*Adgrv1*<sup>+</sup> MOL5/6) and *Clca4a* (*Clca4a*<sup>+</sup> MOL5/6).

310 In the CPZ arm, we observed the emergence of a demyelination associated oligodendrocyte  
311 (DOL) cluster, notable for enrichment for *Tenm4* expression and only weak expression of MOL5/6  
312 and MOL2 markers (Supplemental Figure 4A, C). Two additional clusters emerged, including  
313 *Sox6*-high DOLs (*Sox6*<sup>+</sup> DOL) and interferon responsive oligodendrocytes (IRO) with interferon  
314 pathway gene upregulation (Supplemental Figure 4A, C). Interestingly, pseudotime analysis  
315 indicated that DOLs emerged from MFOLs in the context of cuprizone exposure, suggesting that

316 continual exposure to cuprizone shifts MFOLs from the MOL lineage and towards the DOL state  
317 (Supplemental Figure 4F).

318 PEX5cKO status did not significantly affect cell cluster fractions when assessing fold  
319 change relative to control (Supplemental Figure 4B, D, E), moreover, pseudobulk analysis between  
320 PEX5cKO and control across clusters revealed relatively few DEGs (Supplemental Table 8).  
321 Interestingly, DOLs demonstrated a marked upregulation of *Apod* gene expression, (Supplemental  
322 Figure 4G, H, I) which is associated with oligodendrocyte stress response during ischemia (29,  
323 30), suggestive for an elevated stress-promoting environment secondary to PEX5 knockout in  
324 DMAMs.

325 Immunofluorescence analysis demonstrated that SOX10<sup>+</sup>, ASPA<sup>+</sup> oligodendrocyte cell  
326 counts and PDGFR $\alpha$ <sup>+</sup> OPCs remained comparable between PEX5cKO and control across baseline,  
327 CPZ, and postCPZ conditions (Figure 5). However, we detected reduced myelin basic protein  
328 (MBP) staining in PEX5cKO samples relative to control (Figure 6A, B) at the CPZ and postCPZ  
329 conditions. The MBP deficit between PEX5cKO and control indicated a disruption in  
330 remyelination, which begins by six weeks of cuprizone diet (15). TEM analysis validated a  
331 reduction in myelinated axon counts in PEX5cKO relative to control, most prominently in the  
332 postCPZ arm (Figure 6C, D). Likewise, within the postCPZ condition, we observed an elevated  
333 myelin g-ratio in PEX5cKO samples relative to control, consistent with impaired remyelination  
334 (Figure 6E, F). Furthermore, we observed an aggravated burden of injured axons detectable as  
335 deposits of synaptophysin (SYP) in the corpus callosum of PEX5cKO animals relative to control  
336 during remyelination, indicative of a higher incidence of axon damage associated with impaired  
337 remyelination (Supplemental Figure 4J, K) (31).

338 Impaired myelin debris clearance or loss of pro-remyelination factors provided by  
339 microglia can undermine remyelination (8). Accordingly, within DMAMs we observed a marked  
340 accumulation of degraded myelin basic protein (dMBP), a marker for myelin debris, suggestive of  
341 a disruption in myelin debris clearance (Figure 6G, H). Additionally, we observed a decrease in  
342 pro-remyelinating factor *Igfl* expression in PEX5cKO DMAMs relative to control (Figure 6I).

343 In summary, we report that loss of PEX5 and peroxisome integrity in DMAMs profoundly  
344 disrupts DMAM homeostasis with adverse consequences reflected in impaired remyelination  
345 driven in part by loss of pro-remyelinating factors and impaired myelin debris clearance.

## 346 Discussion

347 Peroxisomes facilitate immunity-related tasks including interferon expression (32), cytokine  
348 release, and pathogen clearance in macrophages (2-4). The present study demonstrates that  
349 peroxisomes also harbor a cell-intrinsic role in microglia critical to remyelination. Key findings  
350 indicate that impaired peroxisome biogenesis redirected the microglial response during  
351 demyelination, expanding a pool of crystal-laden DMAMs deficient in debris clearance and  
352 associated with impaired remyelination, lysosome injury markers, and downregulation of the  
353 critical sterol-exporter gene *ApoE*.

354 Using single nuclei RNA sequencing, marker gene expression coupled with pseudotime  
355 analysis revealed that cuprizone-mediated demyelination robustly recruited DMAMs, a subset of  
356 which acquired a lipid-laden phenotype as indicated by lipid staining and transmission electron  
357 microscopy. PEX5 knockout did not abate the formation of DMAMs but rather expanded an  
358 alternative DMAM state notable for lysosome gene set enrichment, lysosome damage-related  
359 genes *Lgals3* and *Gpnmb*, and exacerbated lipid droplet and crystal burden. *Gpnmb* and *Lgals3*  
360 expression is associated with lysosome stress and damage, including within microglia (33, 34). A

361 recent preprint associated GPNMB (gene product for the *Gpnmb* human ortholog)-enriched foamy  
362 microglia with poorer outcomes in Multiple Sclerosis patients, implicating GPNMB as a potential  
363 marker for lesion exacerbating foamy microglia in Multiple Sclerosis (34). Conversely, the *Lgals3*  
364 gene product, GAL3, is lysosome damage response protein, localizing to the exposed lumen of  
365 injured lysosomes to help mediate lysosome repair and turnover (25, 26). Our findings align with  
366 the above reports, revealing that *Lgals3* and *Gpnmb* expression correlate with lipid-laden microglia  
367 that exhibit features of lysosome stress, namely intralysosomal crystals and increased lysosome  
368 turnover, and with defective remyelination and exacerbated axonal injury. Importantly, our  
369 findings indicate that one pathomechanism leading to lysosome-stressed, foamy microglia  
370 includes defective peroxisome biogenesis.

371         How disruption of peroxisome biogenesis contributes to lipid crystal accumulation remains  
372 undefined, however, *ApoE* gene downregulation suggests that impaired sterol export could  
373 contribute to lipid saturation and crystal precipitation in PEX5cKO DMAMs. *ApoE* gene encodes  
374 for APOE, which is robustly induced in activated microglia (35). APOE knockout mice have  
375 frequently been used as a model for atherosclerosis, giving rise to foamy cells laden with  
376 cholesterol crystals (19, 36). Importantly, APOE loss in microglia exacerbates cholesterol crystal  
377 precipitation during demyelination and impairs remyelination (19). Sterol export pathway gene  
378 products, including APOE, are transcriptionally regulated in part by liver X receptor (LXR), a  
379 nuclear receptor activated by oxysterols and sterol intermediates (37). During demyelination,  
380 DMAMs repurpose *de novo* sterol synthesis to upregulate desmosterol, which activates LXR and  
381 upregulates sterol exporter genes *Abcal* and *ApoE*, facilitating lipid export and protecting against  
382 crystal precipitation (38). PEX5 regulates peroxisome biogenesis through post-translational  
383 mechanisms, mainly by translocating matrix proteins into peroxisomes (39), making direct

384 transcriptional regulation a less plausible mechanism by which PEX5 could affect *ApoE*  
385 expression. However, peroxisomes have long been associated with sterol synthesis and are  
386 reported to house various sterol synthesizing enzymes, including enzymes upstream of  
387 desmosterol (40, 41). Therefore, PEX5 knockout could indirectly affect *ApoE* expression by  
388 undermining peroxisome-dependent synthesis of LXR-activating sterol intermediates. However,  
389 the extent and context of peroxisome contribution to sterol synthesis remains debated (42, 43).

390 An alternative mechanism relating impaired peroxisome integrity to crystal accumulation  
391 stems from our TEM findings. In contrast to PEX5cKO phagocytes, PEX5 intact phagocytes  
392 harbored large (frequently exceeding 1.0  $\mu\text{m}$  in diameter), PEDLs fused with lipid droplets,  
393 structures evocative of lipophagy (21, 22). Moreover, the prevalence for PEDLs correlated with  
394 lipid-laden DMAMs during peak demyelination and resolved with lipid droplet clearance  
395 following cuprizone removal. PEX5cKO DMAMs exhibited fewer and smaller PEDLs, a higher  
396 fraction of which were crystal laden. Moreover, the lower number of PEDLs in PEX5cKO  
397 DMAMs correlated with a higher density of lipid droplets, suggesting an impaired lipophagy, a  
398 critical process in lipid droplet clearance that crosstalks with lipolysis (21, 22). Peroxisomes are  
399 reported to facilitate intracellular cholesterol trafficking between lysosomes and extra-lysosomal  
400 compartments (44). Loss of peroxisome biogenesis factors disrupted sterol export leading to  
401 intracellular sterol accumulation (44). Plausibly, PEX5 depletion in DMAMs undermines the  
402 ability for peroxisomes to extract sterols from lysosomes, contributing to intra-lysosomal sterol  
403 saturation and crystal formation (45). Conversely, peroxisomes can integrate into multi-organelle  
404 units in activated macrophages, wherein peroxisomes facilitated the lipolysis of lipid droplets and  
405 release of inflammatory fatty acids in a PEX5 dependent manner (5). Interestingly, PEX5 has been  
406 implicated in starvation-related lipolysis by facilitating the translocation of adipose triglyceride

407 lipase to lipid droplets (46). Therefore, peroxisome integrity may affect lipophagy by regulating  
408 lipid trafficking from lysosomes or through lipophagy-lipolysis crosstalk (22).

409 Myelin debris can impede remyelination by preventing maturation of newly formed  
410 oligodendrocytes (47, 48). Moreover, maturation of remyelinating oligodendrocytes relies on pro-  
411 remyelinating factors produced by DMAMs, including insulin like growth factor (encoded by *Igf1*)  
412 (8, 49). Our data revealed both a deficit in myelin debris clearance as well reduced expression of  
413 *Igf1* gene, indicating that PEX5cKO DMAMs were less efficient in providing a pro-remyelinating  
414 environment relative to their PEX5 intact counterparts. In macrophages, peroxisomes enable  
415 uptake and clearance of pathogens (3, 50). Interestingly, PEX5cKO DMAMs accumulated myelin  
416 debris relative to control, suggesting a delay in myelin debris degradation following  
417 internalization. Lipid dysregulation and accumulation disrupts lysosome function (51, 52), and  
418 lysosome dysfunction in turn impairs myelin debris clearance (53, 54). Therefore, defective lipid  
419 droplet clearance and elevated lipid and crystal burden in lysosomes could adversely interact with  
420 myelin debris degradation within lysosomes, although it remains plausible that peroxisomes affect  
421 degradation of endo-lysosomal cargo independent of lipid droplet clearing mechanisms, including  
422 via generation of radical nitrogen and oxygen species (3).

423 Our data indicate that peroxisomes are integral to DMAMs and may offer insights to  
424 peroxisomal disorders characterized by disruptions in microglia. Microglial dysfunction features  
425 prominently in adrenoleukodystrophy, a peroxisomal disorder driven by mutations to ATP-binding  
426 cassette subfamily D member 1 (encoded by *ABCD1*) and disruptions to very long chain fatty acid  
427 oxidation (9, 10, 55, 56). *Abcd1* knockout mice challenged with cuprizone and MOG-  
428 immunization exhibited altered neuroinflammatory responses that emulated  
429 adrenoleukodystrophy-related features, including blood brain barrier disruption and perivascular

430 infiltrates, indicating that peroxisome dysmetabolism perturbs neuroinflammatory responses (57).  
431 Our findings further indicate that cell intrinsic disruptions of peroxisomal integrity in microglia  
432 are sufficient to undermine responses to demyelination, reinforcing a critical role for microglial  
433 peroxisome metabolism in peroxisomal disorders such as adrenoleukodystrophy. However, it  
434 should be emphasized that the generalizability of our findings targeting PEX5, which undermines  
435 peroxisome biogenesis and integrity, may be limited in diseases with intact peroxisome biogenesis,  
436 including adrenoleukodystrophy, where PEX5 expression and function are conserved and where  
437 pathogenic mechanisms stem from disruptions in specific peroxisomal pathways rather than global  
438 peroxisome dysfunction.

439 In summary, we report that myelin debris clearance, sterol export, and lipid droplet  
440 metabolism in microglia depend on PEX5, presumably through peroxisome related mechanisms.  
441 Our findings implicate an interrelationship between microglial peroxisomes and remyelination and  
442 encourage further exploration into the mechanisms interrelating peroxisomes and remyelination  
443 promoting properties in microglia.

## 444 **Methods**

### 445 **Sex as a biological variable**

446 Both male and female animals were used with similar findings across both sexes.

### 447 **Mouse strains and alleles**

448 Offspring heterozygous for the *Cx3cr1*<sup>CreERT2-EYFP</sup> allele and homozygous for the *Pex5*<sup>lox</sup> allele  
449 were used for conditional knockout of PEX5 in myeloid cells, including microglia  
450 (*Cx3cr1*<sup>CreERT2/wt</sup>, *Pex5*<sup>lox/lox</sup>). Littermates heterozygous for *Cx3cr1*<sup>CreERT2-EYFP</sup> and heterozygous or  
451 non-carrier for *Pex5*<sup>lox</sup> (*Cx3cr1*<sup>CreERT2/wt</sup>, *Pex5*<sup>lox/wt,wt/wt</sup>) served as controls. To activate Cre-

452 mediated recombination, PEX5cKO and control mice, ages 8-12 weeks, received daily  
453 intraperitoneal injections of 2 mg tamoxifen dissolved in corn oil for five consecutive days.

454 *Cx3cr1*<sup>CreERT2-EYFP</sup> mice (Stock no. 021160) and *Pex5*<sup>lox</sup> mice (Stock no. 031666) were obtained  
455 from The Jackson Laboratory (Bar Harbor, ME, USA) and maintained under pathogen-free  
456 conditions at MD Anderson Cancer Center Animal Facility.

#### 457 **Cuprizone diet**

458 0.2% cuprizone pellet diet (Envigo) was administered ad libitum to experimental mice for 6 weeks.  
459 Tamoxifen was administered two weeks prior to starting CPZ to enable turnover between matrix  
460 protein-intact and -deficient peroxisomes in PEX5 depleted myeloid cells.

#### 461 **Bone marrow derived macrophages**

462 Bone marrow isolate was extracted from femur and tibia using high g-force centrifugation  
463 (>10,000g, 30 seconds, 4°C) and collected in a sterile 1.5 mL microcentrifuge tube. Isolate was  
464 incubated in RBC lysis buffer (Biolegend) on ice for 5 minutes followed by quenching with 10  
465 volumes of ice-cold culture medium. Isolate was filtered through a 70-micron strainer, centrifuged  
466 at 500 g for 10 minutes at 4°C, resuspended in culture medium, and live cells counted using trypan  
467 blue. Isolate was seeded at a concentration of 1.0-2.0 x 10<sup>5</sup> live cells per mL in culture medium  
468 and cultured for 7 days for macrophage differentiation. Culture medium was replaced with fresh  
469 medium every 2-3 days, and consisted of 75% volume of L-glutamine-enriched RPMI1640  
470 medium, 10% fetal bovine serum, and 15% L929 conditioned medium, with 100 U/mL of  
471 penicillin-streptomycin. To deplete PEX5 in vitro, medium was supplemented with 1.0 μM of 4-  
472 hydroxytamoxifen (Sigma H7904) throughout the 7-day differentiation and during experimental  
473 assays for both PEX5cKO and control macrophages. 4-hydroxytamoxifen stock solution was  
474 dissolved in 100% ethanol to 15 mM and added directly to culture medium at 1:15,000 dilution

475 (final concentration of 1.0  $\mu$ M). Fresh 4-hydroxytamoxifen was added when replacing culture  
476 medium every 2-3 days.

#### 477 **L929 conditioned medium**

478 L929 cells (mouse fibroblast cell line, ATCC CCL-1) with low passage number ( $P < 10$ ) were plated  
479 in T175 flasks at a split ratio of 1:10 in DMEM medium with 10% fetal bovine serum and 100  
480 U/mL of penicillin-streptomycin. After 8 days, conditioned medium was harvested and sterile  
481 filtered using 0.22-micron filter and stored at  $-80^{\circ}\text{C}$ . After thawing, conditioned medium was  
482 immediately used or stored in  $4^{\circ}\text{C}$  for no longer than 2 weeks.

#### 483 **Immunofluorescence**

484 For formalin-fixed formaldehyde embedded sections, anesthetized mice were transcardially  
485 perfused with 40 mL of 4.0% paraformaldehyde in PBS. Mouse brain was postfixed in 10%  
486 buffered formalin for minimum 48 hours at room temperature on a rocker. Formalin fixed brains  
487 were dehydrated and embedded in paraffin and sectioned at  $5\mu\text{m}$  thickness onto pre-treated glass  
488 slides. Sections were rehydrated and subjected to heat-mediated antigen retrieval in acidic citrate  
489 buffer with 0.05% Tween20. Sections were blocked with blocking buffer (3% bovine serum  
490 albumin, 1% horse serum in TBS with 0.1% Tween20) for 1 hour and incubated with primary  
491 antibodies in blocking buffer overnight at  $4^{\circ}\text{C}$ . After washing in TBS, sections were incubated with  
492 fluorophore-conjugated secondary antibodies diluted 1:1,000 in blocking buffer for 1 hour at room  
493 temperature protected from light. Slides were incubated with Hoescht 33342 (Invitrogen, H1399)  
494 in TBS for 10 minutes and then washed in TBS. No.1.5 coverslips were mounted with glycerol-  
495 based, anti-fade mounting solution (Invitrogen, 36980) and cured at room temperature protected  
496 from light.

497 For frozen sections, anesthetized mice were transcardially perfused with 40 mL of 4.0%  
498 paraformaldehyde in PBS. Mouse brain was postfixed in ice cold 4.0% paraformaldehyde in PBS  
499 overnight (~12 hours) at 4°C on a rocker. Fixed brains were cryoprotected by incubating in  
500 hyperosmolar sucrose solution (30% sucrose in PBS) at 4°C for 2-3 days. Brains were embedded  
501 in OCT compound and stored at -80°C. OCT-embedded brain tissue was cryo-sectioned into 7µm  
502 thick sections placed on pre-treated glass slides. Sections were rinsed with TBS and permeabilized  
503 using 1.0% Triton-X100 in TBS overnight at 4°C. Following permeabilization, sections were  
504 blocked with blocking buffer (3% bovine serum albumin, 1% horse serum in TBS with 0.1%  
505 Tween20) for 1 hour and incubated with primary antibodies in blocking buffer overnight at 4 °C.  
506 After washing in TBS, sections were incubated with fluorophore-conjugated secondary antibodies  
507 diluted 1:1,000 in blocking buffer for 1 hour at room temperature protected from light. Slides were  
508 incubated with Hoescht 33342 (Invitrogen, H1399) in TBS for 10 minutes and then washed in  
509 TBS. No.1.5 coverslips were mounted with glycerol-based, anti-fade mounting solution  
510 (Invitrogen, 36980) and cured at room temperature protected from light.

511 Primary antibodies included SOX10 (goat, R&D Systems, AF2864), ASPA (rabbit, EMD  
512 Millipore, ABN1698), MBP (mouse, Biolegend, 808401), GAL3 (rat, Biolegend, 125402),  
513 LAMP1 (rabbit, Abcam, ab24170), PDGFR $\alpha$  (rabbit, R&D Systems, AF1062), and SYP (rabbit,  
514 Abcam, ab32127), IBA1 (rabbit, Fujifilm Wako, 019-19741; goat, Fujifilm Wako, 011-27991), and  
515 dMBP (rabbit, Sigma-Aldrich, AB5864).

## 516 **Immunocytochemistry**

517 Bone marrow isolate was cultured on glass coverslips within 6-well plates. Following macrophage  
518 differentiation, coverslips were washed with DPBS and immediately fixed using 4.0%  
519 paraformaldehyde for 10 minutes at room temperature followed by a second DPBS wash. For

520 permeabilization, coverslips were incubated with 0.1% Triton-X100 in D-PBS for 15 minutes at  
521 room temperature followed by a DPBS wash. Coverslips were blocked with blocking buffer (3%  
522 bovine serum albumin, 1% horse serum in TBS with 0.1% Tween20) for 1 hour and incubated with  
523 primary antibodies in blocking buffer overnight at 4°C. After washing in TBS, coverslips were  
524 incubated with fluorophore-conjugated secondary antibodies diluted 1:1,000 in blocking buffer for  
525 1 hour at room temperature protected from light, followed by incubation with Hoescht 33342  
526 (Invitrogen, H1399) in TBS for 10 minutes and a final wash in TBS. Coverslips were inverted onto  
527 pre-treated slides with glycerol-based, anti-fade mounting solution (Invitrogen, 36980) and cured  
528 at room temperature protected from light.

### 529 **Lipid staining**

530 Whole brains were fixed, cryoprotected, OCT-embedded, and frozen per above. After  
531 cryosectioning, 7µm thick sections were incubated in open air at room temperature for 30 minutes  
532 followed by three TBS washes, 10 minutes each. Cryosections were then incubated with 1.0 µM  
533 of BODIPY 493/503 (Invitrogen, D3922), 5.0 µg/mL of DyLight649-conjugated Griffonia  
534 Simplicifolia Lectin I, Isolectin B4 (Vector Laboratories, DL-1208), and propidium iodide  
535 (1:1000) in TBS for 30 minutes at room temperature and protected from light. After washing  
536 sections with TBS, No.1.5 coverslips were mounted using glycerol-based, anti-fade mounting  
537 solution (Invitrogen, 36980). Mounted slides were cured at room temperature protected from light  
538 and stored at -20C.

### 539 **Immunoblotting**

540 Plated bone marrow-derived macrophages were washed twice with sterile DPBS and directly lysed  
541 using ice-cold RIPA lysis buffer (ThermoFisher, 89900) supplemented with protease inhibitor  
542 cocktail (Roche, 11836170001, 1 tablet per 10 mL of RIPA) and phosphatase inhibitor solution

543 (Sigma, P5726, 1:100 dilution in RIPA). Following sonication and centrifugation at >10,000 g for  
544 15 minutes at 4°C, cleared supernatant was stored at -80°C. LDS sample buffer (Invitrogen,  
545 NP0007) was added to 1x concentration and dithiothreitol (DTT, Roche 10197777001) was added  
546 to 50 mM concentration. Samples were heated to 95°C for 5 minutes and loaded onto precast tris-  
547 bis polyacrylamide gels for electrophoresis. Proteins were transferred onto nitrocellulose  
548 membranes via rapid semi-dry protein transfer. Membrane was blocked in 5% non-fat milk in TBS  
549 with 0.1% Tween20 (TBST) for 1 hour at room temperature. Blot was incubated with primary  
550 antibodies diluted 1:500-1000 in TBST with 3% BSA overnight at 4°C. After washing with TBST,  
551 blots were incubated with HRP-conjugated secondaries in TBST with 5% non-fat milk for 1 hour  
552 at room temperature and followed with a second wash in TBST. Blots were incubated with  
553 chemiluminescent substrate (ThermoFisher, 34577) and images acquired using X-ray films.  
554 Primary antibodies included PEX5 (rabbit, Proteintech, 12545-1-1AP), and  $\beta$ -actin (mouse,  
555 Sigma-Aldrich).

#### 556 **RNA purification from bone marrow-derived macrophages**

557 Plated bone marrow-derived macrophages were washed with sterile DPBS twice and directly lysed  
558 with RLT lysis buffer (Qiagen, 79216) supplemented with 2-mercaptoethanol (1:100 dilution).  
559 Lysate was stored at -80°C until downstream RNA extraction. For RNA extraction, frozen lysate  
560 was thawed and then homogenized using QIAshredder columns (Qiagen, 79656) per  
561 manufacturer's instructions. Following homogenization, RNA was purified using the Qiagen  
562 RNeasy mini columns (Qiagen, 74106) with DNA on-column digestion included using RNase-free  
563 DNase I (Qiagen, 79254) per manufacturer's instructions. Total RNA was eluted in nuclease free  
564 water and stored at -80°C.

#### 565 **RTqPCR for bone marrow-derived macrophages**

566 Purified total RNA was reverse transcribed into cDNA using iScript reverse transcriptase (Bio-  
567 Rad, 1708841) per manufacturer's instructions. Real time qPCR was performed using the iTaq  
568 polymerase, universal SYBR green system (Bio-Rad, 1708841) on an Applied Biosystems™ 7500  
569 Real Time PCR system per manufacturer's instructions.

#### 570 **Bulk RNA sequencing for bone marrow-derived macrophages**

571 Purified total RNA with an RNA integrity number (RIN) above 7.0 were submitted to Novogene  
572 Inc. for library preparation and next-generation sequencing. mRNA was enriched and cDNA  
573 libraries were generated from total RNA using the NEBNext Ultra II RNA library prep kit (New  
574 England Biolabs) per manufacturer's instructions. cDNA libraries were pooled and sequenced on  
575 the NovaSeq 6000 to attain  $20 \times 10^6$  paired reads of 150 bases per read (20M, PE150, 6 Gb). Raw  
576 reads were recorded into FASTQ files and were filtered for clean reads by removing (a) adapter-  
577 containing reads, (b) low quality reads having more than 50% bases with a Qscore  $\leq 5$ , and (c)  
578 reads composed of  $>10\%$  undetermined bases.

#### 579 **Bulk RNA sequencing data processing and analysis**

580 Paired reads were aligned to the GRCm38 reference genome using graph-based alignment  
581 (HISAT2, v2.1.0) (58). Aligned sequences were assembled into transcripts using the StringTie  
582 algorithm (StringTie, v2.2.1) (59). Coverage values generated per transcript were converted into  
583 hypothetical gene counts using the formula of gene counts = coverage x (transcript length/read  
584 length). Raw gene counts were transformed using variance stabilizing transformation followed by  
585 dimensionality reduction using principal component analysis to assess for batch effects and  
586 visualize patterns in low dimensional space. Raw gene count were then inputted into the DESeq  
587 pipeline for normalization and DEG analysis (DESeq2, v1.46.0) (60).

#### 588 **Myelin debris isolation and challenge**

589 Whole brains were excised from adult wild-type C57BL6 male mice and minced with a scalpel in  
590 ice-cold 0.32 M sucrose buffer (0.32 M sucrose, 20 mM Tris-HCl, 2 mM Na<sub>2</sub>EDTA, pH 7.45)  
591 supplemented with protease inhibitors (Roche, 11836170001). Minced brains were homogenized  
592 in 0.32 M sucrose buffer using a pre-cooled Tenbroeck tissue grinder (Pyrex, No. 7727-07) on ice  
593 until achieving a smooth, milky homogenate. Homogenate was divided between six ultra-  
594 centrifuge tubes, wherein 13 mL of homogenate was gently layered onto 17 mL of ice-cold 0.83  
595 M sucrose buffer (0.83 M sucrose, 20 mM Tris-HCl, 2 mM Na<sub>2</sub>EDTA, pH 7.45) per tube, with  
596 care taken to avoid mixing between layers. The sucrose gradient was centrifuge at 25,000 RPM  
597 for 1.5 hours at 4°C. The resulting intermediate layer was recovered and re-homogenized using 10  
598 strokes in a pre-cooled Tenbroeck tissue grinder on ice. Crude myelin was diluted in ice-cold  
599 hypotonic Tris-HCl buffer (20 mM Tris-HCl, 2 mM Na<sub>2</sub>EDTA, pH 7.45) and centrifuged at 17,000  
600 RPM for 15 minutes at 4°C. After decanting supernatant, crude myelin was resuspended in Tris-  
601 HCl buffer and pelleted at 17,000 RPM for 15 minutes at 4°C. To enhance myelin purity, crude  
602 myelin was resuspended in 0.32 M sucrose buffer and submitted to a second sucrose gradient  
603 centrifugation followed by two repeated osmotic shocks in hypotonic Tris-HCl buffer as described  
604 above. After the last osmotic shock step, myelin debris was resuspended in ice-cold sterile D-PBS  
605 and transferred to pre-weighted 1.5 mL microtubes. Myelin debris was pelleted at 22,000 g for 10  
606 minutes at 4°C and weighted and then resuspended in sterile DPBS to a stock concentration of 200  
607 mg/mL and stored at -80°C. 10 to 12 adult mice were used per batch of purified myelin. For myelin  
608 debris challenge, myelin debris was thawed and homogenized by passing five times through a  
609 sterile 30G needle. Myelin debris was added to the culture medium to a concentration of 0.50  
610 mg/mL for durations indicated in the study.

#### 611 **Transmission electron microscopy**

612 Anesthetized mice were transcardially perfused with 40 mL of 4.0% paraformaldehyde in PBS.  
613 Mouse brains were hemisected and incubated in EM fixative solution (2.5% EM-grade  
614 glutaraldehyde and 2% EM-grade paraformaldehyde in 0.1 M cacodylate solution buffered to 7.4  
615 pH) at 4°C for minimum 3 days on a rocker. A 1-mm thick coronal section was then taken from  
616 the coronal plane containing dorsal hippocampus (Bregma -1.2mm to -2.2mm), which plane  
617 includes corpus callosum area most affected by 0.2% cuprizone diet. Tissue was resected to  
618 achieve a section area of 1.0 mm<sup>2</sup> and submitted to the High Resolution Electron Microscopy  
619 Facility at MD Anderson for processing and imaging. Samples were washed in 0.1 M sodium  
620 cacodylate buffer, treated with 0.1% Millipore-filtered cacodylate buffered tannic acid, postfixed  
621 with 1% buffered osmium tetroxide, and stained en bloc with 1% Millipore-filtered uranyl acetate.  
622 Samples were dehydrated in increasing concentrations of ethanol, infiltrated, and embedded in  
623 LX-112 medium. Samples were polymerized in a 60°C oven for approximately 3 days. Ultrathin  
624 sections were cut in a Leica Ultracut microtome (Leica, Deerfield, IL), placed on formvar coated  
625 single slot copper grids, stained with uranyl acetate and lead citrate, and examined in a JEM 1010  
626 transmission electron microscope (JEOL, USA, Inc., Peabody, MA) at an accelerating voltage of  
627 80 kV. Digital images were obtained using AMT Imaging System (Advanced Microscopy  
628 Techniques Corp, Danvers, MA).

### 629 **Confocal microscopy and image processing**

630 Confocal imaging was performed using a Leica TCS SP8 laser scanning confocal microscope  
631 equipped with an acousto-optical beam splitter (AOBS). Multiprobe fluorescence imaging with z-  
632 stacking was performed through sequential bidirectional scanning using between-lines acquisition  
633 mode, 600 Hz scan speed, 3000x3000 format, and optimized z-step sizes. For crystals imaging, a  
634 separate channel was configured for reflection microscopy and scanned sequentially with

635 fluorescence acquisition channels. The reflection imaging channel used a PMT detector, with the  
636 AOBS configured to Reflection mode. An 458nm argon laser was used for incident light, and  
637 detection wavelength range was optimized to 455-463nm. Image z stacks were projected onto 2D  
638 composite images using maximum intensity projection method. Image processing and  
639 quantification were conducted using ImageJ software. Acquired images were converted to 8-bit  
640 grey scale and background noise mitigated using a median filter with pixel radius of 2.0. For  
641 particle analysis and counting, images were segmented via thresholding and converted to binary.  
642 Cells counts were obtained via nuclei quantification within segmented cell masks.

### 643 **Brain nuclei isolation**

644 Anesthetized mice were transcardially perfused with 40 mL of PBS. After perfusion, an 8-12 mm<sup>3</sup>  
645 sample of brain tissue containing corpus callosum adjacent was excised and minced into ~1 mm<sup>3</sup>  
646 pieces on wet ice per mouse. Minced tissue was transferred to pre-chilled glass Dounce  
647 homogenizers with homogenization buffer comprised of 250 mM sucrose, 25 mM KCl, 5 mM  
648 MgCl<sub>2</sub>, 1.0 μM DTT, and 0.1% TritonX100 in 10 mM Tris buffer, pH 8.0, supplemented with  
649 RNase (0.4 U/μL RNasin® Promega and 0.2 U/μL SUPERaseIn™ Invitrogen) and protease (1x  
650 cComplete™ cocktail Roche) inhibitors and nuclei acid dyes (1.0 μg/mL PI and 1.0 μg/mL DAPI).  
651 Tissue was homogenized on wet ice using a loose-fitting pestle for 5 strokes followed by a tight-  
652 fitting pestle for 15 strokes. Homogenate was filtered through 50-μm strainers into low DNA  
653 binding microtubes. Nuclei were pelleted at 400 g, 4°C, for 5 minutes and resuspended in isolation  
654 buffer consisting of 1 mg/mL of BSA in nuclease free DPBS supplemented with RNase (0.4 U/μL  
655 RNasin® Promega and 0.2 U/μL SUPERaseIn™ Invitrogen) and protease (1x cComplete™  
656 cocktail Roche) inhibitors and nuclei acid dyes (1.0 μg/mL PI and 1.0 μg/mL DAPI). Nuclei were  
657 filtered through a 40-μm strainer and isolated from debris via fluorescence activated nuclei sorting

658 using singlet and DAPI<sup>+</sup>, PI<sup>+</sup> dual gating, achieving an estimated nuclei concentration of 900 to  
659 1000 nuclei/ $\mu$ L.

### 660 **Single nuclei RNA sequencing**

661 Single nuclei RNA sequencing libraries were constructed in tandem using the 10x Genomics  
662 Chromium Single Cell 3' system (v3.1, dual index) per manufacturer's instructions. Dual indexed  
663 libraries were sequenced using NovaSeq 6000 (Illumina) with 150 bp paired end sequencing at a  
664 target depth of 35,000 reads per nucleus and target sample size of 9000 nuclei per library.  
665 Demultiplexed raw reads were filtered and aligned to the reference genome (mm10) using  
666 cellranger count with intron reads included (10x Genomics Cell Ranger, v7.0.0) (61). Per library,  
667 ambient RNA contamination was scrubbed using decontX (celda, v1.22.1) (62). Low quality  
668 transcriptomes were filtered out using gene count and mitochondrial read cutoffs of 200 and 5.0%,  
669 respectively. Genes detected in fewer than 10 cells were excluded from analysis. Gene counts were  
670 then normalized and scaled using the Seurat LogNormalize method followed by scaling (Seurat,  
671 v5.2.1) (63). Dimensionality reduction and cell clustering were achieved using principal  
672 component analysis (PCA) and the Seurat shared nearest neighbor (SNN) clustering algorithm,  
673 respectively (Seurat, v5.2.1) (63). Doublets were detected for each dataset individually via  
674 scDbIFinder (scDbIFinder, v1.20.2) using an estimated doublet rate of 1.0% per 1000 nuclei  
675 detected (64). After excluding doublets, processed datasets were aggregated into a single library.  
676 Normalization, dimensionality reduction, and clustering were repeated for the aggregated library  
677 using SCTransform (65), PCA, and Seurat SNN clustering algorithm, respectively (Seurat, v5.2.1)  
678 (63). Differentially expressed genes per cluster were identified via the Wilcoxon Rank Sum test  
679 using FindAllMarkers (Seurat, v5.2.1), with log<sub>2</sub> fold change and percent expressed thresholds of  
680 0.25 and 25%, respectively. For pseudobulk analysis, a matrix of gene counts across samples was

681 generated by summing the corrected UMI counts per gene across all cluster-annotated cells per  
682 sample. DEG analysis was performed on the generated gene count matrices using DESeq  
683 (DESeq2, v1.46.0) (60).

#### 684 **Pathway analysis**

685 KEGG (Kyoto Encyclopedia of Genes and Genomes) pathway analysis was performed via  
686 overrepresentation analysis with one-sided Fisher's exact test using enrichKEGG (clusterProfiler,  
687 v4.14.6) (66). Overrepresentation analysis was performed using upregulated (p. adj <0.01, log<sub>2</sub>  
688 fold change > 0.25) and downregulated (p. adj <0.01, log<sub>2</sub> fold change < -0.25) DEGs to determine  
689 enriched and reduced pathways, respectively. Background genes used in pathway analysis between  
690 DMAM2, DMAM1, and DMAM0 clusters required minimum average expression of 0.5 within  
691 the DMAM0 cluster. Background genes used in bulk RNA sequencing pathway analysis required  
692 minimum average expression of 10 across libraries. Minimum and maximum cutoffs for pathway  
693 sizes were 10 and 300, respectively. For bulk RNA sequencing, upstream regulator activity was  
694 inferred from DESeq analysis-derived fold change using Qiagen IPA suite (67). Thresholds for  
695 statistically significant changes in upstream regulator activity included adjusted p value and z-  
696 score cutoffs of 0.05 and |2.0|, respectively.

#### 697 **Enrichment analysis of customized gene sets in bone marrow-derived macrophages**

698 Customized gene sets were generated using annotated microglial cluster marker genes from  
699 published single nuclei RNA sequencing datasets (68, 69). Gene sets were generated by selecting  
700 up to 100 top marker genes (ranked by p) corresponding to annotated clusters. Enrichment of gene  
701 sets in PEX5cKO relative to control was assessed through gene set enrichment analysis using  
702 clusterProfiler (v4.14.6) and gene lists ranked by fold change. An adjusted p value of 0.05 served

703 as a cutoff for statistically enriched (normalized enrichment score > 0) or decreased (normalized  
704 enrichment score < 0) gene sets in PEX5cKO relative to control.

### 705 **Trajectory analysis**

706 Developmental trajectories were inferred using slingshot (slingshot, v 2.14.0) (17). Low-  
707 dimensional space coordinates from uniform manifold approximation and projection and cluster  
708 annotations were inputted into slingshot to map connections between adjacent clusters using a  
709 minimum spanning tree and to infer lineages across mapped connections. The initial clusters within  
710 microglial and oligodendrocyte lineages were specified based on prior knowledge using  
711 established gene markers for homeostatic microglia and committed oligodendrocyte precursors,  
712 respectively. Smooth lineage curves were generated using a resolution of up to 400 cells.

### 713 **Statistics**

714 Statistical analysis was conducted in R. Unpaired, two-tailed t test was used for comparisons  
715 between two groups. FDR method was used for multiple testing correction. For comparison  
716 between multiple groups, one-way ANOVA was conducted followed by Tukey HSD for post-hoc  
717 testing. A *P* value less than 0.05 was considered significant. Number of animals or wells used per  
718 experiment are indicated in the corresponding figures. For immunoblotting and RT-qPCR,  
719 representative data from multiple independent replicates are shown. No statistical methods were  
720 used to predetermine sample size. No blinding or randomization was implemented during  
721 experiments.

### 722 **Study approval**

723 Mouse work was conducted in accordance with protocols approved by the Institutional Animal  
724 Care and Use Committee of the University of Texas MD Anderson Cancer Center.

### 725 **Data availability**

726 Underlying data for the figures presented in the main text and supplemental material are available  
727 within the Supporting Data Values file. Raw and processed data for bone marrow-derived  
728 macrophage bulk RNA sequencing and mouse brain single cell RNA sequencing are available on  
729 the Gene Expression Omnibus repository within the GSE255159 and GSE272138 series,  
730 respectively. The analytic code used for RNA-seq analysis is publicly available on GitHub at  
731 <https://github.com/loui-kwam/PEX5> (GitHub ID: loui-kwam).

732 **Author contributions**

733 JABV contributed to study conception and design, optimization and conduction of experiments,  
734 data analysis and interpretation, and manuscript drafting and editing. YLPS assisted and performed  
735 immunofluorescence sample prep and immunoblotting. KAS assisted and performed  
736 immunofluorescence sample prep, image acquisition, and analysis. YG and XZ assisted with  
737 animal husbandry and provided support during experiments. JH contributed to study conception  
738 and design, data interpretation, and manuscript editing.

739 **Acknowledgements**

740 This work was supported by the NIH through F31NS124110 and R01NS127933 grants. We would  
741 like to thank the editorial support provided by Sarah J. Bronson, Scientific Editor at the MD  
742 Anderson Cancer Center Research Medical Library. We acknowledge the cancer center support  
743 grant (CCSG) NIH P30CA016672 and thank Kenneth Dunner Jr. at the High Resolution Electron  
744 Microscopy Facility for assistance with transmission electron microscopy sample prep and  
745 imaging. We also extend our gratitude to the Research Animal Support Facility at Houston and  
746 MDACC Veterinary Medicine and Surgery department for their support related to animal  
747 husbandry and veterinary care.

748

749 **References**

- 750 1. Lodhi IJ, and Semenkovich CF. Peroxisomes: a nexus for lipid metabolism and cellular  
751 signaling. *Cell Metab.* 2014;19(3):380-92.
- 752 2. Di Cara F, et al. The peroxisome: an up-and-coming organelle in immunometabolism.  
753 *Trends Cell Biol.* 2023;33(1):70-86.
- 754 3. Di Cara F, et al. Peroxisome-Mediated Metabolism Is Required for Immune Response to  
755 Microbial Infection. *Immunity.* 2017;47(1):93-106 e7.
- 756 4. Nath AS, et al. Modulation of the cell membrane lipid milieu by peroxisomal beta-  
757 oxidation induces Rho1 signaling to trigger inflammatory responses. *Cell Rep.*  
758 2022;38(9):110433.
- 759 5. Zimmermann JA, et al. Functional multi-organelle units control inflammatory lipid  
760 metabolism of macrophages. *Nat Cell Biol.* 2024;26(8):1261-73.
- 761 6. Beckers L, et al. Microglia lacking a peroxisomal beta-oxidation enzyme chronically alter  
762 their inflammatory profile without evoking neuronal and behavioral deficits. *J*  
763 *Neuroinflammation.* 2019;16(1):61.
- 764 7. Verheijden S, et al. Identification of a chronic non-neurodegenerative microglia activation  
765 state in a mouse model of peroxisomal beta-oxidation deficiency. *Glia.* 2015;63(9):1606-  
766 20.
- 767 8. Lloyd AF, and Miron VE. The pro-remyelination properties of microglia in the central  
768 nervous system. *Nat Rev Neurol.* 2019;15(8):447-58.
- 769 9. Eichler FS, et al. Is microglial apoptosis an early pathogenic change in cerebral X-linked  
770 adrenoleukodystrophy? *Ann Neurol.* 2008;63(6):729-42.

- 771 10. Bergner CG, et al. Microglia damage precedes major myelin breakdown in X-linked  
772 adrenoleukodystrophy and metachromatic leukodystrophy. *Glia*. 2019;67(6):1196-209.
- 773 11. Sahasrabudde V, and Ghosh HS. Cx3Cr1-Cre induction leads to microglial activation and  
774 IFN-1 signaling caused by DNA damage in early postnatal brain. *Cell Rep*.  
775 2022;38(3):110252.
- 776 12. Baes M, et al. Generation of Pex5-loxP mice allowing the conditional elimination of  
777 peroxisomes. *Genesis*. 2002;32(2):177-8.
- 778 13. Santos MJ, et al. Peroxisomal membrane ghosts in Zellweger syndrome--aberrant organelle  
779 assembly. *Science*. 1988;239(4847):1536-8.
- 780 14. Huybrechts SJ, et al. Peroxisome dynamics in cultured mammalian cells. *Traffic*.  
781 2009;10(11):1722-33.
- 782 15. Zirngibl M, et al. Oligodendrocyte death and myelin loss in the cuprizone model: an  
783 updated overview of the intrinsic and extrinsic causes of cuprizone demyelination. *Mol*  
784 *Neurodegener*. 2022;17(1):34.
- 785 16. Butovsky O, and Weiner HL. Microglial signatures and their role in health and disease. *Nat*  
786 *Rev Neurosci*. 2018;19(10):622-35.
- 787 17. Street K, et al. Slingshot: cell lineage and pseudotime inference for single-cell  
788 transcriptomics. *BMC Genomics*. 2018;19(1):477.
- 789 18. Grajchen E, Hendriks JJA, and Bogie JFJ. The physiology of foamy phagocytes in multiple  
790 sclerosis. *Acta Neuropathol Commun*. 2018;6(1):124.
- 791 19. Cantuti-Castelvetri L, et al. Defective cholesterol clearance limits remyelination in the aged  
792 central nervous system. *Science*. 2018;359(6376):684-8.

- 793 20. Loving BA, and Bruce KD. Lipid and Lipoprotein Metabolism in Microglia. *Front Physiol.*  
794 2020;11:393.
- 795 21. Singh R, et al. Autophagy regulates lipid metabolism. *Nature.* 2009;458(7242):1131-5.
- 796 22. Zechner R, Madeo F, and Kratky D. Cytosolic lipolysis and lipophagy: two sides of the  
797 same coin. *Nat Rev Mol Cell Biol.* 2017;18(11):671-84.
- 798 23. Chemke J, Livni N, and Rosenmann E. Adrenoleukodystrophy: evidence for cytoplasmic  
799 inclusions in white blood cells. *Pediatr Pathol.* 1986;6(2-3):173-9.
- 800 24. Ghatak NR, et al. Morphology and distribution of cytoplasmic inclusions in  
801 adrenoleukodystrophy. *J Neurol Sci.* 1981;50(3):391-8.
- 802 25. Jia J, et al. Galectin-3 Coordinates a Cellular System for Lysosomal Repair and Removal.  
803 *Dev Cell.* 2020;52(1):69-87 e8.
- 804 26. Kumar S, et al. Galectins and TRIMs directly interact and orchestrate autophagic response  
805 to endomembrane damage. *Autophagy.* 2017;13(6):1086-7.
- 806 27. Garcia-Revilla J, et al. Galectin-3, a rising star in modulating microglia activation under  
807 conditions of neurodegeneration. *Cell Death Dis.* 2022;13(7):628.
- 808 28. Aits S, et al. Sensitive detection of lysosomal membrane permeabilization by lysosomal  
809 galectin puncta assay. *Autophagy.* 2015;11(8):1408-24.
- 810 29. Dassati S, Waldner A, and Schweigreiter R. Apolipoprotein D takes center stage in the  
811 stress response of the aging and degenerative brain. *Neurobiol Aging.* 2014;35(7):1632-42.
- 812 30. Rickhag M, et al. Apolipoprotein D is elevated in oligodendrocytes in the peri-infarct  
813 region after experimental stroke: influence of enriched environment. *J Cereb Blood Flow*  
814 *Metab.* 2008;28(3):551-62.


- 815 31. Gudi V, et al. Synaptophysin Is a Reliable Marker for Axonal Damage. *J Neuropathol Exp*  
816 *Neurol.* 2017;76(2):109-25.
- 817 32. Dixit E, et al. Peroxisomes are signaling platforms for antiviral innate immunity. *Cell.*  
818 2010;141(4):668-81.
- 819 33. van der Lienden MJC, et al. Glycoprotein Non-Metastatic Protein B: An Emerging  
820 Biomarker for Lysosomal Dysfunction in Macrophages. *Int J Mol Sci.* 2018;20(1).
- 821 34. van der Vliet D, et al. Foamy microglia link oxylipins to disease progression in multiple  
822 sclerosis. *bioRxiv.* 2024:2024.10.18.619040.
- 823 35. Deczkowska A, et al. Disease-Associated Microglia: A Universal Immune Sensor of  
824 Neurodegeneration. *Cell.* 2018;173(5):1073-81.
- 825 36. Meir KS, and Leitersdorf E. Atherosclerosis in the apolipoprotein-E-deficient mouse: a  
826 decade of progress. *Arterioscler Thromb Vasc Biol.* 2004;24(6):1006-14.
- 827 37. Wang B, and Tontonoz P. Liver X receptors in lipid signalling and membrane homeostasis.  
828 *Nat Rev Endocrinol.* 2018;14(8):452-63.
- 829 38. Berghoff SA, et al. Microglia facilitate repair of demyelinated lesions via post-squalene  
830 sterol synthesis. *Nat Neurosci.* 2021;24(1):47-60.
- 831 39. Skowrya ML, Feng P, and Rapoport TA. Towards solving the mystery of peroxisomal  
832 matrix protein import. *Trends Cell Biol.* 2024;34(5):388-405.
- 833 40. Charles KN, et al. Functional Peroxisomes Are Essential for Efficient Cholesterol Sensing  
834 and Synthesis. *Front Cell Dev Biol.* 2020;8:560266.
- 835 41. Faust PL, and Kovacs WJ. Cholesterol biosynthesis and ER stress in peroxisome  
836 deficiency. *Biochimie.* 2014;98:75-85.

- 837 42. Hogenboom S, et al. Absence of functional peroxisomes does not lead to deficiency of  
838 enzymes involved in cholesterol biosynthesis. *J Lipid Res.* 2002;43(1):90-8.
- 839 43. Hogenboom S, Wanders RJ, and Waterham HR. Cholesterol biosynthesis is not defective  
840 in peroxisome biogenesis defective fibroblasts. *Mol Genet Metab.* 2003;80(3):290-5.
- 841 44. Chu BB, et al. Cholesterol transport through lysosome-peroxisome membrane contacts.  
842 *Cell.* 2015;161(2):291-306.
- 843 45. Varsano N, et al. Two polymorphic cholesterol monohydrate crystal structures form in  
844 macrophage culture models of atherosclerosis. *Proc Natl Acad Sci U S A.*  
845 2018;115(30):7662-9.
- 846 46. Kong J, et al. Spatiotemporal contact between peroxisomes and lipid droplets regulates  
847 fasting-induced lipolysis via PEX5. *Nat Commun.* 2020;11(1):578.
- 848 47. Kotter MR, et al. Myelin impairs CNS remyelination by inhibiting oligodendrocyte  
849 precursor cell differentiation. *J Neurosci.* 2006;26(1):328-32.
- 850 48. Lampron A, et al. Inefficient clearance of myelin debris by microglia impairs remyelinating  
851 processes. *J Exp Med.* 2015;212(4):481-95.
- 852 49. Mason JL, et al. Insulin-like growth factor (IGF) signaling through type 1 IGF receptor  
853 plays an important role in remyelination. *J Neurosci.* 2003;23(20):7710-8.
- 854 50. Pellegrino E, et al. Peroxisomal ROS control cytosolic Mycobacterium tuberculosis  
855 replication in human macrophages. *J Cell Biol.* 2023;222(12).
- 856 51. Fraldi A, et al. Lysosomal fusion and SNARE function are impaired by cholesterol  
857 accumulation in lysosomal storage disorders. *EMBO J.* 2010;29(21):3607-20.
- 858 52. Cox BE, et al. Effects of cellular cholesterol loading on macrophage foam cell lysosome  
859 acidification. *J Lipid Res.* 2007;48(5):1012-21.

- 860 53. Wu Y, et al. Microglial lysosome dysfunction contributes to white matter pathology and  
861 TDP-43 proteinopathy in GRN-associated FTD. *Cell Rep.* 2021;36(8):109581.
- 862 54. Safaiyan S, et al. Age-related myelin degradation burdens the clearance function of  
863 microglia during aging. *Nat Neurosci.* 2016;19(8):995-8.
- 864 55. Jaspers YRJ, et al. Lipidomic biomarkers in plasma correlate with disease severity in  
865 adrenoleukodystrophy. *Commun Med (Lond).* 2024;4(1):175.
- 866 56. Moser HW, Mahmood A, and Raymond GV. X-linked adrenoleukodystrophy. *Nat Clin  
867 Pract Neurol.* 2007;3(3):140-51.
- 868 57. Hashemi E, et al. A Novel Mouse Model for Cerebral Inflammatory Demyelination in X-  
869 Linked Adrenoleukodystrophy: Insights into Pathogenesis and Potential Therapeutic  
870 Targets. *Ann Neurol.* 2025;97(2):296-312.
- 871 58. Kim D, et al. Graph-based genome alignment and genotyping with HISAT2 and HISAT-  
872 genotype. *Nat Biotechnol.* 2019;37(8):907-15.
- 873 59. Pertea M, et al. Transcript-level expression analysis of RNA-seq experiments with HISAT,  
874 StringTie and Ballgown. *Nat Protoc.* 2016;11(9):1650-67.
- 875 60. Love MI, Huber W, and Anders S. Moderated estimation of fold change and dispersion for  
876 RNA-seq data with DESeq2. *Genome Biol.* 2014;15(12):550.
- 877 61. Zheng GX, et al. Massively parallel digital transcriptional profiling of single cells. *Nat  
878 Commun.* 2017;8:14049.
- 879 62. Yang S, et al. Decontamination of ambient RNA in single-cell RNA-seq with DecontX.  
880 *Genome Biol.* 2020;21(1):57.
- 881 63. Hao Y, et al. Dictionary learning for integrative, multimodal and scalable single-cell  
882 analysis. *Nat Biotechnol.* 2024;42(2):293-304.

- 883 64. Germain PL, et al. Doublet identification in single-cell sequencing data using scDbIFinder.  
884 *F1000Res.* 2021;10:979.
- 885 65. Hafemeister C, and Satija R. Normalization and variance stabilization of single-cell RNA-  
886 seq data using regularized negative binomial regression. *Genome Biol.* 2019;20(1):296.
- 887 66. Yu G, et al. clusterProfiler: an R package for comparing biological themes among gene  
888 clusters. *OMICS.* 2012;16(5):284-7.
- 889 67. Kramer A, et al. Causal analysis approaches in Ingenuity Pathway Analysis.  
890 *Bioinformatics.* 2014;30(4):523-30.
- 891 68. Absinta M, et al. A lymphocyte-microglia-astrocyte axis in chronic active multiple  
892 sclerosis. *Nature.* 2021;597(7878):709-14.
- 893 69. Androvic P, et al. Spatial Transcriptomics-correlated Electron Microscopy maps  
894 transcriptional and ultrastructural responses to brain injury. *Nat Commun.*  
895 2023;14(1):4115.  
896

898 **Figure 1. DMAM2 cluster emerges from PEX5cKO microglia following demyelination.**



899

900 (A) UMAP of combined whole brain nuclei detected from baseline and CPZ conditions colored

901 according to major cell type identity. (B) Cell count and cell fraction per major cell type identified

902 within baseline and CPZ conditions across PEX5cKO and control samples. (C) UMAP of immune

903 subclusters colored according to subcluster identity and split by conditions. (D) UMAP of immune


904 subclusters colored according to genotype and split by condition. (E) Average gene expression of

905 marker genes per immune subcluster. Dot color and size correspond to average expression and  
906 percent expressed, respectively. **(F)** Cell count and cell fraction per immune subcluster identified  
907 within each library generated from baseline (n=1 per genotype) and CPZ (n=3 per genotype)  
908 conditions. **(G)** Cell fraction  $\log_2$  fold change relative to control per immune subcluster. Individual  
909 datapoints correspond to libraries generated from the CPZ condition. Bars correspond to the mean  
910  $\log_2$  fold change. Unpaired, two-tailed t test, not significant (ns)  $p>0.05$ , \*  $p<0.05$ . **(H)** Inferred  
911 lineages for microglial subclusters derived from slingshot analysis superimposed onto immune cell  
912 UMAP, with the Homeostatic subcluster designated as the origin cluster. **(I)** Pseudotime trajectory  
913 for DMAM1 lineage. **(J)** Pseudotime trajectory for DMAM2 lineage  
914 UMAP, uniform manifold approximation and projection.

915

916

917 **Figure 2. PEX5 loss impairs *ApoE* expression, aggravating lipid droplet burden and**  
 918 **promoting lipid crystal accumulation.**



919  
 920 (A) Upregulated and downregulated pseudobulk-derived DEGs per immune subcluster  
 921 over bars indicate DEG count >0. (B) Venn diagram triangulating downregulated DEGs detected  
 922 in DMAM0, DMAM1, and Intermediate subclusters. (C) *ApoE* average expression per immune  
 923 subcluster split by genotype. (D) Per immune subcluster *ApoE* scaled expression across libraries  
 924 within CPZ condition. (E) Representative TEM micrographs of phagocytes. Red circles and red


925 arrowheads mark lipid droplets and crystal clefts, respectively. Non-phagocyte area is shaded blue  
926 to ease visualization of phagocyte. Scale bar = 2.0  $\mu\text{m}$ . **(F)** Lipid droplet<sup>+</sup> cells as fraction of total  
927 cells imaged. **(G)** Lipid droplet count per cell assessed. **(H)** Crystal positive cells as fraction of  
928 total cells imaged. **(I)** Crystal cleft count detected per cell. **(J)** Representative micrographs for  
929 BODIPY and lectin staining within CPZ condition. Nuclei are stained with propidium iodide dye.  
930 Scale bar = 10  $\mu\text{m}$ . **(K)** BODIPY<sup>+</sup> cell count per  $\text{mm}^2$ . **(L)** BODIPY<sup>+</sup> droplet count per lectin<sup>+</sup> cell.  
931 **(M)** Representative micrographs of dual confocal and reflective microscopy imaging lectin stain  
932 and reflective particles. Nuclei are stained with propidium iodide. Scale bar = 10  $\mu\text{m}$ . **(N)** Average  
933 area of reflective particle microclusters.

934 For **(E – N)**, representative images were acquired from corpus callosum and cells analyzed and  
935 quantitated were imaged from corpus callosum. For **(F, H, K, and N)**, individual datapoints  
936 correspond to biological replicates. For **(F and H)**, square and error bar correspond to mean and  
937 standard deviation, respectively. For **(G, I, and L)**, datapoints represent dataset outliers. Cell  
938 number assessed per group are given below each box plot. Statistical analysis for **(F – I, K, L, and**  
939 **N)** involved ANOVA followed by Tukey HSD. Not significant (ns)  $p.\text{adj} > 0.05$ ,  $*p.\text{adj} < 0.05$ ,  
940  $**p.\text{adj} < 0.01$ ,  $***p.\text{adj} < 0.001$ ,  $****p.\text{adj} < 0.0001$ .

941

942

943 **Figure 3. PEX5cKO phagocytes exhibit intralysosomal crystals and cytosolic curvilinear**  
 944 **profiles.**




945  
 946 (A) Representative transmission electron micrographs of PEDLs indicated with a red-colored  
 947 outline imaged phagocyte. Yellow asterisks mark PEDLs fusing with lipid droplets, evocative of  
 948 lipophagy. Yellow arrows indicate intralysosomal crystal clefts. Scale bar = 1.0  $\mu\text{m}$ . (B) PEDL-  
 949 positive cell quantification as fraction of total cells imaged. Individual datapoints correspond to  
 950 biological replicates. Square and error bar correspond to mean and standard deviation, respectively.  
 951 (C) PEDL count per cell. Datapoints correspond to outliers and number of cells assessed are given

952 below each box plot. **(D)** Area,  $\mu\text{m}^2$ , per crystal-free PEDL grouped by genotype and condition.  
953 PEDL count and median area are indicated in parentheses. Datapoints correspond to outliers. **(E)**  
954 Fraction of summed PEDLs corresponding to crystal-free and -positive PEDLs, grouped by  
955 genotype and condition. Crystal-positive PEDL counts are indicated below stacked bars. Crystal-  
956 free and -positive sums are indicated in parentheses. **(F)** Representative transmission electron  
957 micrographs of curvilinear profiles detected in phagocytes within corpus callosum following  
958 cuprizone exposure. Green arrowheads indicate representative curvilinear profiles. Yellow border  
959 surrounds cluster of curvilinear profiles. Scale bars = 1.0  $\mu\text{m}$ . **(G)** Curvilinear profile positive cells  
960 as fraction of total cells imaged. Individual datapoints correspond to biological replicates.  
961 All representative images were acquired from corpus callosum. Quantifications only used cells  
962 imaged from corpus callosum. Statistical analysis for **(B, C, and G)** included ANOVA followed by  
963 Tukey HSD. Not significant (ns)  $p.\text{adj} > 0.05$ ,  $*p.\text{adj} < 0.05$ ,  $**p.\text{adj} < 0.01$ ,  $****p.\text{adj} < 0.0001$ .  
964 **(D)** Unpaired, two-tailed t test,  $*p < 0.05$

965

966

967 **Figure 4. Exacerbated GAL3 response and lysosome turnover in PEX5cKO DMAMs.**



968

969 (A) Representative micrographs for GAL3 immunofluorescence within corpus callosum. Nuclei  
970 are stained with Hoescht dye. Scale bar = 25  $\mu$ m. (B) GAL3<sup>+</sup> cell count per mm<sup>2</sup> of corpus  
971 callosum. Individual datapoints correspond to biological replicates. (C) Average GAL3  
972 fluorescence integrated density per GAL3<sup>+</sup> cell. Individual datapoints correspond to biological  
973 replicates. (D) Representative micrographs of GAL3<sup>+</sup> cells with punctae (arrows), condensed  
974 (arrowheads), and mixed staining patterns, which frequently colocalize with LAMP1 staining


975 (asterisk). Scale bar = 5  $\mu\text{m}$ . **(E)** Percentage of GAL3<sup>+</sup> cells subdivided by staining pattern  
976 represented in D. Individual datapoints correspond to biological replicates. Color corresponds to  
977 genotype and datapoint shape corresponds to condition. **(F)** Upregulated (red,  $-\log_{10}p.\text{adj} > 2.0$ ,  
978  $\log_2\text{fold change} > 0.25$ ) and downregulated (blue,  $-\log_{10}p.\text{adj} > 2.0$ ,  $\log_2\text{fold change} < -0.25$ ) DEGs  
979 detected in the DMAM2 subcluster relative to DMAM0 (left) and DMAM1 (right) subclusters,  
980 respectively. **(G)** Top 3 enriched and reduced KEGG pathways in DMAM2 relative to DMAM0  
981 (left) and DMAM1 (right) subclusters, respectively.

982 For **(A – E)**, representative images were acquired from corpus callosum. Quantifications only used  
983 cells imaged from corpus callosum. Statistical analysis for **(B and C)** included ANOVA followed  
984 by Tukey HSD. **(E)** FDR adjusted, two tailed t test. Not significant (ns)  $p.\text{adj} > 0.05$ ,  $*p.\text{adj} < 0.05$ ,  
985  $**p.\text{adj} < 0.01$ ,  $***p.\text{adj} < 0.001$ ,  $****p.\text{adj} < 0.0001$ . KEGG, Kyoto Encyclopedia of Genes and  
986 Genomes

987

988

989 **Figure 5. Oligodendrocyte density remains comparable between PEX5cKO and control**  
 990 **genotypes across conditions.**



991  
 992 **(A)** Representative confocal micrographs for ASPA and SOX10 immunofluorescence. Nuclei are  
 993 stained with Hoescht dye. Scale bar = 75  $\mu$ m. **(B)** SOX10<sup>+</sup> cell count per mm<sup>2</sup> in corpus callosum.  
 994 **(C)** ASPA<sup>+</sup>, SOX10<sup>+</sup> cell count per mm<sup>2</sup> in corpus callosum. **(D)** Representative confocal  
 995 micrographs for PDGFR $\alpha$ <sup>+</sup> immunofluorescence. Nuclei are stained with Hoescht dye. Scale bar  
 996 = 10  $\mu$ m. **(E)** PDGFR $\alpha$ <sup>+</sup> cell count per mm<sup>2</sup> in corpus callosum.

997 For (A – E), representative images were acquired from corpus callosum. Quantifications only used  
998 cells imaged from corpus callosum. Individual datapoints per box plot correspond to biological  
999 replicates. Statistical analysis for (B, C, and E) included ANOVA followed by Tukey HSD, ns  
1000 p.adj >0.05, \*\*\* p.adj <0.001, \*\*\*\*p.adj <0.0001. CPZ, cuprizone-fed, postCPZ, post cuprizone  
1001 removal, ns, not significant.

1002

1003



1012 regression. Number of myelinated axons analyzed are given and colored according to genotype.  
1013 **(F)** Myelinated axon g-ratio binned across axon diameters rounded to the nearest 0.1 decimal.  
1014 Number of myelinated axons analyzed are given below each box plot. **(G)** Representative confocal  
1015 micrographs for IBA1, GAL3, and dMBP immunofluorescence within the corpus callosum. Nuclei  
1016 are stained with Hoescht dye. Scale bar = 10  $\mu\text{m}$ . **(H)** dMBP<sup>+</sup> area fluorescence per IBA1<sup>+</sup>, GAL3<sup>+</sup>  
1017 cell assessed. Datapoints correspond to biological replicates. **(I)** Average gene expression of *Igfl*  
1018 scaled across biological replicates per immune subcluster detected within the CPZ condition. Dot  
1019 color and size correspond to scaled gene expression and percent expressed, respectively.  
1020 Statistical analysis for **(B)** and **(C)** included ANOVA followed by Tukey HSD comparison. **(F)**  
1021 FDR adjusted, two tailed t test. Not significant (ns)  $p.\text{adj} >0.05$ ,  $*p.\text{adj} <0.05$ ,  $**p.\text{adj} <0.01$ ,  
1022  $***p.\text{adj} <0.001$ ,  $****p.\text{adj} <0.0001$ . **(H)** Unpaired, two tailed t test,  $*p <0.05$ .  
1023 For **(A – H)**, representative images were acquired from corpus callosum. Quantifications only used  
1024 cells imaged from corpus callosum. For **(C)**, **(E)**, and **(F)**, mice used per genotype for baseline,  
1025 CPZ, and postCPZ conditions were 2, 3, and 4, respectively.  
1026